Rivaroxaban Versus Standard Anticoagulation for Acute Childhood. Design of the EINSTEIN-Jr Phase III Study

Thrombosis Journal

16, 1-11

DOI: 10.1186/s12959-018-0188-y

Citation Report

#	Article	IF	Citations
1	Clinical Presentation and Therapeutic Management of Venous Thrombosis in Young Children: A Retrospective Analysis. Thrombosis Journal, 2018, 16, 1-9.	2.9	18
2	Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?. Pediatric Cardiology, 2019, 40, 1431-1438.	1.9	9
3	Bodyweight-Adjusted Rivaroxaban for Children With Venous Thromboembolism (EINSTEIN-Jr): Results From Three Multicentre, Single-Arm, Phase 2 Studies. Lancet Haematology,the, 2019, 6, e500-e509.	14.9	75
4	Rivaroxaban and the EINSTEIN Clinical Trial Programme. Blood Coagulation and Fibrinolysis, 2019, 30, 85.	1.0	33
5	Rivaroxaban Compared With Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: A Randomised, Controlled, Phase 3 Trial. Lancet Haematology,the, 2020, 7, e18-e27.	14.9	307
6	Shunt Thrombosis in Pediatric Patients Undergoing Staged Cardiac Reconstruction for Cyanotic Congenital Heart Disease. Progress in Pediatric Cardiology, 2020, 56, 101190.	0.4	4
7	New Options for Anticoagulation in Congenital and Pediatric Acquired Heart Disease. Progress in Pediatric Cardiology, 2020, 59, 101301.	0.4	1
8	Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-Related Venous Thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 2020, 4, 4632-4639.	6.3	51
9	Venous Thromboembolism in Children: From Diagnosis to Management. International Journal of Environmental Research and Public Health, 2020, 17, 4993.	4.2	49
10	Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. An Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	5.0	87
11	Population Pharmacokinetic Analysis of Rivaroxaban in Children and Comparison to Prospective Physiologically-Based Pharmacokinetic Predictions. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1195-1207.	3.0	18
12	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. Journal of Clinical Pharmacology, 2022, 62, 220-231.	2.4	13
13	Safety and Efficacy of Rivaroxaban in Pediatric Cerebral Venous Thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	6.3	116
14	Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. Journal of Pediatrics, 2022, 240, 14-23.	3.2	6
15	Innovation in Children's Anticoagulant Drugs. Iranian Journal of Pediatrics, 2020, .	0.4	0
16	Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous Thrombosis. Pediatric Neurology, 2022, 128, 20-24.	2.3	17
17	Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options. Frontiers in Pediatrics, 2022, 10, 855162.	2.4	20
18	Model-Informed Bridging of Rivaroxaban Doses for Thromboprophylaxis in Pediatric Patients Aged 9 Years and Older With Congenital Heart Disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1111-1121.	3.0	8

#	Article	IF	Citations
19	Current Antithrombotic Therapy Strategies in Children With a Focus on Off-Label Direct Oral Anticoagulants—A Narrative Review. Children, 2022, 9, 1093.	3.0	6
20	Anticoagulation in Pediatric Cancer–Associated Venous Thromboembolism: A Subgroup Analysis of EINSTEIN-Jr. Blood Advances, 2022, 6, 5821-5828.	6.3	20
21	Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: Review of Approved Products Rivaroxaban and Dabigatran. Frontiers in Pediatrics, 2022, 10, 1005098.	2.4	10
22	Real World Experience of Efficacy and Safety of Rivaroxaban in Paediatric Venous Thromboembolism. Thrombosis Research, 2023, 221, 92-96.	2.9	19
23	Just DOAC: Use of Direct-Acting Oral Anticoagulants in Pediatrics. American Journal of Health-System Pharmacy, 2023, 80, 412-422.	1.4	8
24	Pharmacokinetics of a Microdosed Cocktail of Three Direct Oral Anticoagulants in Children With Congenital Heart Defects: Study Protocol for a Single-Centre Clinical Trial (DOAC-Child). BMJ Paediatrics Open, 2023, 7, e001662.	2.4	1
25	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Pulmonary Embolism. Cochrane Database of Systematic Reviews, 2023, 4, CD010957.	6.9	12
26	Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors Versus Conventional Anticoagulants for the Treatment of Deep Vein Thrombosis. Cochrane Database of Systematic Reviews, 2023, 4, CD010956.	6.9	27
27	Pediatric Thromboprophylaxis of Large Coronary Artery Aneurysm Using Rivaroxaban. Journal of Pediatric Hematology/Oncology, 2023, 45, 356.	0.9	8
28	Management of Venous Thromboembolism in Pediatric Patients: Quality Assessment of Clinical Practice Guidelines and Variations in Recommendations. Thrombosis Research, 2023, 226, 107-116.	2.9	6
29	Evaluation, Analysis, and Reporting of Medication Adherence for Clinical Trials of Anticoagulants in Children: Guidance From the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2024, 22, 2081-2092.	5.0	1
30	Systematic Analysis of the Design, Methodology, and Patient Population Characteristics of the Pediatric Direct Oral Anticoagulant Trials of Venous Thromboembolism Treatment. Journal of Thrombosis and Haemostasis, 2025, 23, 1315-1331.	5.0	5
31	Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-Analysis and Pharmacovigilance Study. Paediatric Drugs, 2025, 27, 1-16.	4.6	2
32	Interim Results on the Impact of Rivaroxaban Dose Escalation on Recanalisation Time in Paediatric Patients With Venous Thromboembolism. Hamostaseologie, 2025, 45, T-02-12.	1.5	0
33	Antiphospholipid Syndrome Presenting as Isolated Renal Vein Thrombosis: A Case Report and Review of the Literature. Journal of Medical Case Reports, 2025, 19, 123.	1.1	2
34	Extended-Phase Anticoagulant Treatment of Acute Venous Thromboembolism in Children: A Cohort Study From the EINSTEIN-Jr Phase 3 Trial. Lancet Haematology,the, 2025, 12, e357-e364.	14.9	9
35	Gefäßerkrankungen bei Kindern und Jugendlichen. , 2025, .		0
36	Direct Oral Anticoagulant Rivaroxaban for Secondary Prevention of Catheter-Related Thrombosis in Children With Intestinal Failure: Real-Life Data. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103231.	3.3	5

#	Article	IF	Citations
37	Considerations of Safety for Women Prescribed Apixaban or Rivaroxaban Who Breastfeed-a Physiologically Based Pharmacokinetic Analysis. Journal of Thrombosis and Haemostasis, 2026, 24, 520-529.	5.0	8
38	Rivaroxaban for Pediatric Venous Thromboembolism in Routine Clinical Practice: Effectiveness and Safety From a Real-World Cohort. Thrombosis Research, 2026, 263, 109730.	2.9	0
39	Can Edoxaban and Rivaroxaban Be Prescribed for Breastfeeding Mothers? The New Horizons Clinical Trial. Journal of Thrombosis and Haemostasis, 2026, .	5.0	1